Effective delivery of large genes by dual AAV vectors
The present invention relates to constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5 Kb.
1. A dual construct system to express the coding sequence of a gene of interest in a host cell, said coding sequence consisting of a 5′end portion and of a 3′end portion, said dual construct system comprising:
a) a first plasmid comprising, in a 5′-3′ direction:
a 5′-inverted terminal repeat (5′-ITR) sequence;
a promoter sequence;
the 5′ end portion of said coding sequence, said 5′end portion being operably linked to and under control of said promoter;
a nucleic acid sequence of a splicing donor signal; and
a 3′-inverted terminal repeat (3′-ITR) sequence; and
b) a second plasmid comprising, in a 5′-3′ direction:
a 5′-inverted terminal repeat (5′-ITR) sequence;
a nucleic acid sequence of a splicing acceptor signal;
the 3′end of said coding sequence;
a poly-adenylation signal nucleic acid sequence;
a 3′-inverted terminal repeat (3′-ITR) sequence;
wherein the nucleotide sequence of the respective ITRs is obtained from an adeno-associated virus (AAV) of the same AAV serotype or from an AAV of a different serotype;
wherein said first plasmid further comprises a nucleic acid sequence of a recombinogenic region in 5′ position of the 3′ITR of said first plasmid, and wherein said second plasmid further comprises a nucleic acid sequence of a recombinogenic region in 3′ position of the 5′-ITR of said second plasmid; and
wherein the recombinogenic region is an F1 phage recombinogenic region that consists of the sequence:
(SEQ ID NO: 3)
GGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACA
AAAATTTAACGCGAATTTTAACAAAAT.
2. The dual construct system according to claim 1 , wherein upon introduction of said first plasmid and said second plasmid into the host cell, said coding sequence reconstitutes by means of the splicing donor and the splicing acceptor signals.
3. The dual construct system according to claim 1 , wherein the 3′-ITR of the first plasmid and the 5′-ITR of the second plasmid are from the same AAV serotype.
4. The dual construct system according to claim 1 , wherein the 5′-ITR and 3′-ITR of the first plasmid and the 5′-ITR and 3′-ITR of the second plasmid are respectively from different AAV serotypes.
5. The dual construct system according to claim 1 , wherein the 5′-ITR of the first plasmid and the 3′-ITR of the second plasmid are from different AAV serotypes.
6. The dual construct system according to claim 1 , wherein the coding sequence is split into the 5′ end portion and the 3′ end portion at a natural exon-exon junction.
7. The dual construct system according to claim 1 , wherein the nucleic acid sequence of the splicing donor signal comprises the sequence:
(SEQ ID NO: 1)
GTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGG
CTTGTCGAGACAGAGAAGACTCTTGCGTTTCT.
8. The dual construct system according to claim 1 , wherein the nucleic acid sequence of the splicing acceptor signal comprises the sequence
(SEQ ID NO: 2)
GATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCACA
G.
9. The dual construct system according to claim 1 , wherein the first plasmid further comprises at least one enhancer sequence, operably linked to the coding sequence.
10. The dual construct system according to claim 1 , wherein the coding sequence is a nucleotide sequence encoding a protein able to correct an inherited retinal degeneration.
11. The dual construct system according to claim 10 , wherein the coding sequence is selected from the group consisting of: ABCA4, MYO7A, CEP290, CDH23, EYS, USH2a, GPR98 and ALMS1.
12. A dual viral vector system comprising:
a) a first viral vector containing the first plasmid, and
b) a second viral vector containing the second plasmid,
wherein said first and said second plasmids are as defined in claim 1 , and
wherein the vectors are adeno-associated virus (AAV) vectors.
13. The dual viral vector system according to claim 12 , wherein the adeno-associated virus (AAV) vectors are the same or different AAV serotypes.
14. The dual viral vector system according to claim 12 , wherein the AAV vectors have a serotype selected from the group consisting of serotype 2, serotype 8, serotype 5, serotype 7 and serotype 9.
15. An isolated host cell transformed with the dual viral vector system according to claim 12 .
16. A pharmaceutical composition comprising the dual construct system according to claim 1 , and a pharmaceutically acceptable vehicle.
17. A method for treating a subject having a disease characterized by a retinal degeneration comprising subretinally administering to said subject an effective amount of the dual viral vector system according to claim 12 .
18. A pharmaceutical composition comprising the dual viral vector system according to claim 12 and a pharmaceutically acceptable vehicle.
19. A pharmaceutical composition comprising the isolated host cell according to claim 15 and a pharmaceutically acceptable vehicle.